Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

French Deal Spree Fueled By Easy Money -- WSJ

share with twitter share with LinkedIn share with facebook
share via e-mail
05/22/2019 | 02:48am EDT

By Patricia Kowsmann and Tom Fairless

The European Central Bank's efforts to revive growth have spurred a flurry of investment and deal making. One problem is, a bunch of it is happening outside of Europe.

French companies in particular have been aggressive in using the ECB's easy-money policies to snap up foreign competitors and to expand overseas, fleeing anemic growth and high taxes at home. French corporate indebtedness has risen so quickly it has drawn the eye of wary regulators.

French corporations spent around $100 billion on foreign acquisitions in each of the past two years, the highest amount since 2008, according to data provider Dealogic. The U.S. was the No. 1 destination for French outbound deals in four of the past five years. Eighteen U.S. deals have been announced or completed by French companies so far this year.

In April, French advertising giant Publicis Groupe SA said it was buying Texas-based Alliance Data Systems Corp.'s marketing-services business for $4.4 billion, partly funded with cheap debt. Finance chief Jean-Michel Etienne told investors the deal will generate profits from the get-go because of low funding costs.

French drugmaker Sanofi SA made two large purchases last year, including of U.S.-based hemophilia drugmaker Bioverativ Inc. for $11.6 billion. Sanofi had increased its indebtedness to around EUR25 billion ($27.9 billion) by December from EUR14 billion in 2013. It last tapped the bond market in March, selling EUR2 billion in notes at interest rates ranging from 0% to 1.25%.

"Obviously, cost of funding is one of the key elements to take into account for debt-funded acquisitions," a company spokesman said.

Sanofi added that while it has been taking advantage of the low rates, it is able to create enough cash flow, particularly post-acquisition, to repay what it owes.

The ECB's aggressive stimulus policies, in place since 2014, include negative interest rates and a EUR180 billion corporate bond-buying program, which stopped expanding last year but continues to reinvest proceeds from maturing bonds.

French food group Danone SA bought U.S. organic-foods producer WhiteWave Foods for $10.4 billion in 2017. It replaced some U.S. debt outstanding at WhiteWave that was carrying a 5.375% interest for a 1.75%-coupon euro bond, "taking advantage of the current exceptionally attractive hybrid market conditions," it said at the time.

The ECB has purchased the debt of Publicis, Sanofi and Danone, receiving zero or close to zero interest rates on those bonds.

A factor that has held back even greater use of euro debt for overseas purchases is the cost companies pay to convert euros into dollars and hedge interest rate exposure. A derivative used by companies known as a cross-currency basis swap has made it expensive at times to borrow in euros to fund dollar deals.

Sanofi, for instance, also has borrowed in dollars, paying higher rates, but kept the borrowing aligned with revenue it makes in dollars.

France has the biggest number of large, listed corporations in the eurozone, accounting for more than a third of the Euro Stoxx 50 index of leading eurozone stocks. Companies from Germany, Europe's largest economy, tend to be smaller, reliant on bank borrowing -- and more suspicious of debt.

Regulators in France and the ECB are worried that the sharp increase in corporate debt could threaten the region's financial system. The French central bank has twice ordered the country's lenders over the past year to set aside more capital against corporate loans.

French corporate debt has surged -- to more than 143% of gross domestic product, a 27 percentage-point increase since the 2008 financial crisis, according to data from the Bank for International Settlements. That is even as European companies have generally been paying down debt.

In Germany, corporate debt is 55% of gross domestic product and has been falling. U.S. corporate debt stands at 74% of GDP.

"ECB monetary policy is too loose for France and Germany," said Joerg Kraemer, chief economist at Commerzbank in Frankfurt. The one-size-fits-all stimulus has shored up growth in southern Europe but fueled excessive lending in some northern countries, he said.

French firms are also using debt markets to lend more to subsidiaries abroad. Intragroup loans more than doubled to 16.9% of GDP in 2017 from 6.7% in 1999, according to ratings firm Standard & Poor's.

French industrial gas supplier Air Liquide SA had lent EUR15.4 billion to group entities at the end of last year, more than double from 2013. Sizable acquisitions in recent years have made the U.S. its biggest revenue contributor.

The flurry of deals represents a late globalization strategy by French corporations mimicking overseas expansion drives by U.S. and German multinationals in the 1980s and 1990s, respectively, said Sylvain Broyer, an economist for S&P Global Ratings.

"It resembles a venture capital strategy," since French investments abroad deliver much higher yields than foreign investment in France, Mr. Broyer said.

Write to Patricia Kowsmann at patricia.kowsmann@wsj.com and Tom Fairless at tom.fairless@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
ONE STOP SYSTEMS, INC. -1.98% 2.48 Delayed Quote.30.41%
SANOFI -0.55% 82.03 Delayed Quote.9.17%
SANOFI -0.88% 82.07 Real-time Quote.8.47%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
10/20SAFRAN : Star French banker Pigasse resigns from Lazard
10/18Board of directors meeting of Sanofi - Aventis Pakistan Limited
10/18SANOFI : Zantac OTC recalled over cancer-causing chemical
10/18Sanofi pulls Zantac from U.S. and Canada after carcinogen found
10/18SANOFI : Recalls Over-the-Counter Zantac in U.S. and Canada
10/16SANOFI : opens its first digitally-enabled, continuous manufacturing facility us..
10/16Factbox - How are businesses preparing for a 'no-deal Brexit'?
10/15SANOFI : opens its first digitally-enabled, continuous manufacturing facility; u..
10/11SANOFI : - Innovative treatment Cablivi granted new technology payment for Medic..
10/09SANOFI : appeals revocation of Dengvaxia's registration
More news
Financials (EUR)
Sales 2019 36 350 M
EBIT 2019 9 502 M
Net income 2019 4 369 M
Debt 2019 14 929 M
Yield 2019 3,84%
P/E ratio 2019 25,4x
P/E ratio 2020 17,7x
EV / Sales2019 3,24x
EV / Sales2020 3,04x
Capitalization 103 B
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 24
Average target price 91,02  €
Last Close Price 82,07  €
Spread / Highest target 21,8%
Spread / Average Target 10,9%
Spread / Lowest Target -3,74%
EPS Revisions
Paul Hudson Chief Executive Officer
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Ameet Nathwani Chief Medical & Digital Officer
John C. Reed Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI8.47%115 572
JOHNSON & JOHNSON-1.05%337 866
ROCHE HOLDING AG18.88%250 723
MERCK AND COMPANY10.82%216 403
PFIZER-16.47%201 662
NOVARTIS15.10%197 593